4 completed, 3 recruiting, 2 not yet recruiting, 2 unknown. 12 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 4, Recruiting 3, Not yet recruiting 2, Unknown 2, Terminated 1 |
| Phase 1 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow Lethargy: new trials by email Literature Review of Lethargy trials Research Report on Lethargy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy IRL757, Placebo - PARKINSON DISEASE (Disorder), Apathy | Phase 1 / Phase 2 | Recruiting | Integrative Research Laboratories AB | 75 | 2026-02-18 | 2026-09-03 |
| Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia intermittent theta burst stimulation (iTBS), Methylphenidate (MPH) - Alzheimer s Disease, Alzheimer Dementia (AD) | Phase 2 | Recruiting | Sunnybrook Health Sciences Centre | 12 | 2026-01-01 | 2025-12-12 |
| Accelerated rTMS vs. Sham for Stroke Apathy MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active), MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham), Brainsight Neuronavigation System - Apathy, Stroke | Phase 1 / Phase 2 | Recruiting | Medical University of South Carolina | 40 | 2025-08-08 | 2026-07-08 |
| Effort and Antidepressant Study Test Escitalopram 10mg, Placebo 10 mg - Effort Based Decision Making, Prosocial Behavior | Phase 1 / Phase 2 | Not yet recruiting | University of Oxford | 50 | 2025-01-01 | 2024-11-20 |
| Methylphenidate for Apathy in Veterans With Parkinson's Disease Psychosocial intervention, Methylphenidate - Parkinson Disease, Apathy | Phase 2 | Not yet recruiting | Ralph H. Johnson VA Medical Center | 60 | 2024-01-01 | 2022-12-30 |
| A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy CVL-871 1.0 mg, CVL-871 3.0 mg, Placebo - Apathy in Dementia | Phase 2 | Terminated | AbbVie | 41 | 2021-06-22 | 2026-03-11 |
| Intranasal Oxytocin for Frontotemporal Dementia Syntocinon - Frontotemporal Dementia | Phase 2 | Unknown | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 112 | 2018-01-31 | 2023-12-15 |
| Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease Magnetic Stimulator Magstim Rapid 2, Sham Magnetic Stimulator - Alzheimer's Disease, Apathy | Phase 2 | Unknown | Federal University of Minas Gerais | 40 | 2013-06-01 | 2013-06-25 |
| Apathy Cure Through Bupropion in Huntington's Disease Bupropion, Placebo - Apathy, Huntington's Disease | Phase 2 | Completed | Charite University, Berlin, Germany | 40 | 2012-06-01 | 2014-09-09 |
| Effects of Transcranial Direct Current Stimulation on the Apathy of Alzheimer's Disease Transcranial direct current stimulation - Apathy, Alzheimer's Disease | Phase 2 | Completed | University of Sao Paulo | 40 | 2012-01-01 | 2014-01-09 |
| Apathy in Dementia Methylphenidate Trial (ADMET) Methylphenidate, placebo, Psychosocial intervention - Apathy, Alzheimer's Disease | Phase 2 | Completed | Johns Hopkins Bloomberg School of Public Health | 60 | 2010-06-01 | 2018-06-12 |
| Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants Therapeutic Hypothermia, Standard of Care Therapy - Urea Cycle Disorders, Organic Acidemias | Phase 2 | Completed | Uta Lichter-Konecki | 5 | 2007-08-01 | 2015-06-01 |
Alzheimer Disease (4) · Dementia (4) · Parkinson Disease (2) · Altruism (1) · Argininosuccinic Aciduria (1) · Brain Diseases (1) · Brain Edema (1) · Carbamoyl-Phosphate Synthase I Deficiency Disease (1) · Citrullinemia (1) · Coma (1) · Depression (1) · Frontotemporal Dementia (1) · Huntington Disease (1) · Hyperammonemia (1)
Nervous System Diseases (12) · Neurobehavioral Manifestations (12) · Neurologic Manifestations (12) · Pathological Conditions, Signs and Symptoms (12) · Signs and Symptoms (12) · Central Nervous System Diseases (11) · Brain Diseases (10) · Neurodegenerative Diseases (8) · Mental Disorders (7) · Neurocognitive Disorders (7) · Tauopathies (4) · Basal Ganglia Diseases (3) · Dementia (3) · Movement Disorders (3) · Behavior (2)
Methylphenidate (3) · Psychosocial Intervention (2) · Bupropion (1) · Continuous Renal Replacement Therapy (1) · Cool-Down Exercise (1) · Cryotherapy (1) · Dialysis (1) · Drug Delivery Systems (1) · Escitalopram (1) · Hypothermia, Induced (1) · Oxytocin (1) · Renal Dialysis (1) · Transcranial Direct Current Stimulation (1) · Transcranial Magnetic Stimulation (1)
AbbVie (1) · Charite University, Berlin, Germany (1) · Federal University of Minas Gerais (1) · Integrative Research Laboratories AB (1) · Johns Hopkins Bloomberg School of Public Health (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Medical University of South Carolina (1) · Ralph H. Johnson VA Medical Center (1) · Sunnybrook Health Sciences Centre (1) · University of Oxford (1) · University of Sao Paulo (1) · Uta Lichter-Konecki (1)
United States (5) · Canada (4) · Brazil (2) · Germany (2) · Bulgaria (1) · Poland (1) · Spain (1)
Krista Lanctot, PhD (2) · Breno S Diniz, MD, PhD (1) · Catherine J Harmer, PhD (1) · Claudia K Suemoto, MD, PhD (1) · Ester Nakamura-Palacios, MD, PhD (1) · Felipe Fregni, MD, PhD, MPH (1) · Jacobo Mintzer, MD, MBA (1) · Josef Priller, MD (1) · Kevin Caulfield, PhD (1) · Lisa McTeague, PhD (1) · Parneet Grewal, PhD (1) · Paul Rosenberg, MD (1) · Ricardo Nitrini, MD, PhD (1)
PMID 24021498, PMID 24262299, PMID 30261917, PMID 39862881
2009 (1), R01AG033032 (1)